ResearcherChinese University of Hong KongActive in the last 2 years

Tsz Tung Kwong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1870-1046; OpenAlex author ID A5028142218. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2024: 1 paper · 2025: none · 2026: 1 paper

Papers 2

RAS-targeted therapies for pancreatic cancer. First author DOI 10.1016/j.esmogo.2026.100414 ↗
PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-24-0425 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Landon Long Chan · 2 shared papers, 2024–2026 · strength 0.66
- Paper RAS-targeted therapies for pancreatic cancer. DOI 10.1016/j.esmogo.2026.100414 ↗
- Paper PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer. DOI 10.1158/2767-9764.crc-24-0425 ↗
Stephen Lam Chan · 2 shared papers, 2024–2026 · strength 0.66
- Paper RAS-targeted therapies for pancreatic cancer. DOI 10.1016/j.esmogo.2026.100414 ↗
- Paper PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer. DOI 10.1158/2767-9764.crc-24-0425 ↗
Ksh Chok · 1 shared paper, 2024 · strength 0.23
- Paper PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer. DOI 10.1158/2767-9764.crc-24-0425 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.